Articles

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

ImmunoGen Inc., Waltham, MA, USA
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
ImmunoGen Inc., Waltham, MA, USA
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
ImmunoGen Inc., Waltham, MA, USA
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland;Swiss Institute of Bioinformatics, Lausanne, Switzerland and
ImmunoGen Inc., Waltham, MA, USA
ImmunoGen Inc., Waltham, MA, USA
Cytogenetics Laboratory, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland;Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
ImmunoGen Inc., Waltham, MA, USA
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
Vol. 104 No. 8 (2019): August, 2019 https://doi.org/10.3324/haematol.2018.211011